Apigenin exerts anticancer effects on human cervical cancer cells via induction of apoptosis and regulation of Raf/MEK/ERK signalling pathway
Abstract
Purpose: To investigate the anticancer activity of apigenin on human cervical cancer cells.
Methods: The anti-proliferative effects of apigenin on HeLa cervical cancer cells were determined by 3-(4,5-dimethylthiazol-2-yl)- )-2,5-diphenyltetrazolium bromide (MTT) and clonogenic assays, while its effect on apoptosis was assayed by DAPI and annexin V/PI double staining. Expression of proteins was assessed by immunoblotting.
Results: Apigenin exerted anticancer effects on HeLa cervical cancer cells with an IC50 of 15 μM, and also reduced the colony formation of HeLa cells. These antiproliferative effects were due to induction of apoptosis as indicated by DAPI and annexin V/PI staining. Apigenin altered Bax/Bcl-2 ratio, thereby triggering apoptosis, and also inhibited the Raf/MEK/ERK signalling pathway.
Conclusion: These results indicate that apigenin suppresses the growth of cervical cancer cells and may prove to be an important molecule for the treatment of cervical cancer.
Keywords: Cervical cancer, Apigenin, Apoptosis, Bax
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.
